TFA
CPRX

Toth Financial Advisory’s Catalyst Pharmaceutical CPRX Stock Holding History

Toth Financial Advisory’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-750
Closed -$17.5K – 951
2025
Q4 		$17.5K Sell
750
-1,400
-65% -$31.2K ﹤0.01% 489
2025
Q3 		$42.4K Sell
2,150
-59,200
-96% -$1.22M ﹤0.01% 376
2025
Q2 		$1.33M Buy
61,350
+1,825
+3% +$43.1K 0.16% 110
2025
Q1 		$1.44M Buy
59,525
+5,275
+10% +$119K 0.17% 108
2024
Q4 		$1.13M Buy
54,250
+3,750
+7% +$80.6K 0.13% 119
2024
Q3 		$1M Buy
+50,500
New +$936K 0.12% 122
2024
Q2 		– Sell
-33,800
Closed -$539K – 760
2024
Q1 		$539K Buy
33,800
+31,300
+1,252% +$472K 0.07% 160
2023
Q4 		$42K Hold
2,500
– – 0.01% 311
2023
Q3 		$29.2K Hold
2,500
– – ﹤0.01% 318
2023
Q2 		$33.6K Hold
2,500
– – ﹤0.01% 317
2023
Q1 		$41.5K Buy
2,500
+2,000
+400% +$33K 0.01% 293
2022
Q4 		$9.3K Hold
500
– – ﹤0.01% 449
2022
Q3 		$6K Buy
+500
New +$5.93K ﹤0.01% 530

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Toth Financial Advisory's CPRX Position: Q1 2026 in Review

Toth Financial Advisory sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 750 shares — an estimated $17.5K sold.

Toth Financial Advisory first reported a position in CPRX in Q3 2022 and held it in 13 quarters. The position peaked at $1.44M in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Toth Financial Advisory reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Toth Financial Advisory sold 750 Catalyst Pharmaceutical shares in Q1 2026, an estimated $17.5K.
  • Toth Financial Advisory first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 13 quarters.
  • Toth Financial Advisory's Catalyst Pharmaceutical position peaked at $1.44M in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Toth Financial Advisory's 13F filing for Q1 2026, filed 16 Apr 2026.